Arch Biopartners (Arch) has received US patent for its brain tumor cell targeting technology, which protects novel synthetic peptides that target and attach human brain tumor initiating cells (BTICs) and invasive glioma cells (IGCs). The ...
Arch Biopartners has signed an agreement to buy a new diagnostic technology, which identifies irritable bowel syndrome (IBS). The technology helps clinicians to diagnose IBS that causes frequent abdominal discomfort, pain and ...
Tags: diagnostic technology, IBS, Arch Biopartners, clinical technology